10x Genomics (TXG) Capital Expenditures (2018 - 2026)

10x Genomics has disclosed Capital Expenditures across 9 years of filings, most recently posting $118000.0 for Q1 2026.

• Capital Expenditures for Q1 2026 came in at $118000.0, down 93.77% year-over-year; the trailing twelve-month figure through Mar 2026 was $4.2 million (down 66.42% YoY), and the FY2025 annual result was $5.9 million, down 52.11% from the prior year.
• Capital Expenditures came in at $118000.0 for Q1 2026 at 10x Genomics, down from $1.8 million in the prior quarter.
• In the past five years, Capital Expenditures ranged from a high of $102.4 million in Q4 2022 to a low of -$27.0 million in Q3 2023.
• The 5-year median for Capital Expenditures is $1.8 million (2025), against an average of $9.0 million.
• Across the five-year window, Capital Expenditures sank 139.41% in 2022 and surged 2597.88% in 2024, its largest moves.
• 10x Genomics' Capital Expenditures stood at $102.4 million in 2022, then tumbled by 99.59% to $424000.0 in 2023, then soared by 2597.88% to $11.4 million in 2024, then sank by 84.47% to $1.8 million in 2025, then sank by 93.36% to $118000.0 in 2026.
• The last three Capital Expenditures figures came in at $118000.0 (Q1 2026), $1.8 million (Q4 2025), and $687000.0 (Q3 2025), per Business Quant data.